| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Awakn Life Sciences partners with the University of Nottingham to advance in vivo testing of its aminoindane therapy for PTSD, ...
Awakn Life Sciences expands its private placement to $2 million, closing the fourth tranche with $394,286 raised to accelerate ...
President Biden Approves Psychedelics Clinical Trials For Active Military Members President Biden signed into law the 2024 Nat...
Awakn Life Sciences (OTC: AWKNF), a clinical-stage biotechnology company specializing in the development of ketamine-assisted t...
GOP Candidate Vivek Ramaswamy Wants Legal Psychedelics And Cannabis For PTSD In New Veterans Plan
The U.K. Medicines and Healthcare Regulatory Agency (MHRA) has green-lighted two separate Phase 3 trials conducted by Compass P...
Professor David Nutt, a cognitive sciences, addiction, cannabis and psychedelics researcher, has been ranked the #1 psychopharm...